Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $191 from $185 and keeps an Equal Weight rating on the shares. Neurocrine delivered a “strong” Q1 and Ingrezza demand is tracking above FY26 guidance, while the early Crenessity launch metrics in CAH show “meaningful share capture,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
- Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
- Neurocrine Remains Top Pick on Durable Multi‑Year Growth Outlook; Buy Rating Reiterated with Unchanged $200 Price Target
- Neurocrine Biosciences Delivers Record Quarter, Eyes 2027
- Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand